The result of 95.7% 1-year survival in a large, multicenter, international phase 2 trial of a nonmyeloablative haploidentical bone marrow transplant (BMT) with posttransplant cyclophosphamide for GVHD prophylaxis for pediatric and adult patients with sickle cell disease has opened a new door of opportunity for curative therapy. The approach uses a less expensive and labor-intensive approach that expands its availability to countries outside of well-resourced areas of the world. Professional illustration by Patrick Lane, ScEYEnce Studios.